Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: A systematic review

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 6, 2012, Pages 787-793

  Yilmaz, Taygan ^a   Cordero Coma, Miguel ^b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b HOSPITAL DE LEÓN   (Spain)

Author keywords

Bevacizumab; Branch retinal vein occlusion; Macular edema

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; BRANCH RETINAL VEIN OCCLUSION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RETINA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84864308748     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2016-6     Document Type: Review

References (30)

1. David R, Zangwill L, Badarna M, Yassur Y (1988) Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197(2):69-74
2. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133-141, discussion 141-133
3. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114(10):1243-1247 (Pubitemid 26338856)
4. Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye 25 (8):981-988
5. Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M, Dehghan MH, Azarmina M, Esfahani MR (2011) Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol 249(2):193-200
6. Ehlers JP, Fekrat S (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56(4):281-299
7. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271-282
8. McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5):835-854
9. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50(3):1025-1032
10. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22(1):42-48
11. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92(3):351-355 (Pubitemid 351363529)
12. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518-522 (Pubitemid 351497981)
13. Chen CH, Chen YH, Wu PC, Chen YJ, Lee JJ, Liu YC, Kuo HK (2010) Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 33(4):424-435
14. Micieli JA, Micieli A, Smith AF (2010) Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol 45(3):231-238
15. Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309(6964):1286-1291 (Pubitemid 24340510)
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12 (Pubitemid 26120810)
17. Higgins J, Green S (2006) Cochrane Handbook for Systematic Reviews of Interventions 4.2.6: Section 6. The Cochrane Library 4
18. Çekiç O, Cakir M, Yazici AT, Alagoz N, Bozkurt E, Faruk Yilmaz O (2010) A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res 35(10):925-929
19. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29(4):511-515
20. Wu WC, Cheng KC, Wu HJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 23(12):2215-2222
21. Fung AE, Bhisitkul RB (2008) Safety monitoring with ocular antivascular endothelial growth factor therapies. Br J Ophthalmol 92 (12):1573-1574
22. Network Diabetic Retinopathy Clinical Research, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10):1860-1867
23. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 364(20):1897-1908
24. Roth DB, King A, Weiss M, Klein D (2009) Systemic adverse events after bevacizumab. Ophthalmology 116(6):1226 e1221
25. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116(6):1142-1150
26. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ (2009). Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 116(5):902-911, quiz 912-903
27. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594-1602
28. Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, Schmetterer L, Schmidt-Erfurth U (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52(6):3046-3050
29. Gillies MC (2006) What we don't know about Avastin might hurt us. Arch Ophthalmol 124(10):1478-1479 (Pubitemid 44537150)
30. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28(2):131-138 (Pubitemid 32538057)